BMS’ Sotyktu Receives FDA Expansion in Psoriatic Arthritis

Key Takeaways

• First oral TYK2 inhibitor approved for psoriatic arthritis
• Sotyktu showed 54% ACR20 response at week 16
• Potential to become BMS blockbuster, $291M 2025 sales
• Expands BMS portfolio against Amgen’s Otezla
• Offers oral option, no boxed warning

Summary

Bristol Myers Squibb received FDA approval expanding Sotyktu (deucravacitinib) to treat adults with active psoriatic arthritis, making it the first oral selective TYK2 inhibitor for this indication. The label extension is backed by the POETYK PsA-1 and PsA-2 trials, where 54% of patients achieved a 20% improvement in disease activity at week 16. Sotyktu, already approved for plaque psoriasis, generated $291 million in 2025 sales and now targets a broader psoriatic disease market. The drug competes directly with Amgen’s Otezla, positioning BMS for potential blockbuster status.

Pulse Analysis

Psoriatic arthritis affects up to 30% of psoriasis patients, combining joint inflammation with skin lesions that impair quality of life. Oral disease‑modifying agents have been scarce, leaving clinicians reliant on biologics and injectable small molecules. Sotyktu’s mechanism—selective inhibition of TYK2, a key node in cytokine signaling—addresses both skin and joint pathways, positioning it as a versatile tool for comprehensive disease management. Its oral formulation simplifies adherence and reduces the logistical burdens associated with infusion centers, a critical advantage in chronic care settings.

The POETYK PsA‑1 and PsA‑2 trials demonstrated statistically significant improvements, with more than half of participants achieving ACR20 responses and a notable proportion reaching ACR50 thresholds. Compared with existing oral options like apremilast, Sotyktu delivers higher efficacy while maintaining a clean safety profile, lacking a boxed warning and presenting manageable adverse events. These data reinforce its role as a competitive alternative for patients who have exhausted first‑line therapies or prefer to avoid injections.

From a commercial perspective, the expanded indication unlocks a multi‑billion‑dollar market. BMS’s 2025 sales of $291 million hint at rapid uptake, and the drug’s potential to eclipse Otezla could shift market share toward a more profitable, patent‑protected portfolio. The approval also validates BMS’s strategic acquisition of Celgene’s pipeline, illustrating how legacy assets can be repurposed for new indications. Looking ahead, broader insurance coverage and real‑world evidence will determine whether Sotyktu achieves true blockbuster status and reshapes treatment algorithms for psoriatic disease.